For example, the recent SAVE-MORE trial showed that anakinra, which blocks both IL-1α and IL-1β, reduced the risk of clinical progression in patients with COVID-19, when co-administered with dexamethasone (49). This evidence concerns the gene IL1B and COVID-19.